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Background: Although Alzheimer’s disease (AD) is a central nervous system disease and type 2 
diabetes mellitus (T2DM) is a metabolic disorder, an increasing number of genetic 
epidemiological studies show clear link between AD and T2DM. The current approach to 
uncovering the shared pathways between AD and T2DM involves association analysis; however, 
such analyses lack power to discover the mechanisms of the diseases. 
Methods: We develop novel statistical methods to shift the current paradigm of genetic analysis 
from association analysis to deep causal inference for uncovering the shared mechanisms 
between AD and T2DM, and develop pipelines  to infer multilevel omics causal networks which 
lead to shifting  the current paradigm of genetic analysis from genetic analysis alone to 
integrated causal genomic, epigenomic, transcriptional and phenotypic data analysis. To discover  
common causal paths from genetic variants to AD and T2DM,  we also develop algorithms that 
can automatically search the causal paths from genetic variants to diseases and  
Results: The proposed methods and algorithms are applied to ROSMAP dataset with 432 
individuals who simultaneously had genotype, RNA-seq, DNA methylation and some 
phenotypes.  We construct multi-omics causal networks and  identify 13 shared causal genes, 16 
shared causal pathways between AD and T2DM, and 754 gene expression and 101 gene 
methylation nodes that were connected to both AD and T2DM in multi-omics causal 
networks.      
Conclusions: The results of application of the proposed pipelines for identifying causal paths to 
real data analysis of AD and T2DM provided strong evidence to support the link between AD 
and T2DM and unraveled causal mechanism to explain this link. 
Keywords: Causal inference, additive noise models, structural equations, shared genes and 
pathways, Alzheimer’s Disease and type 2 diabetes.  
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Background 
Although Alzheimer’s dementia is a central nervous system disease and type 2 diabetes mellitus 
(T2DM) is a metabolic disorder, an increasing number of epidemiological and genetic 
epidemiological studies show clear link between Alzheimer’s dementia and T2DM. Alzheimer’s 
dementia with great economic, political and social consequences is a progressive, irreversible 
degenerative disease of the brain and is the most common cause of dementia due to the gradual 
accumulation of amyloid-beta (𝐴𝛽) and twisting of tau protein [1, 2], and other common brain 
pathologies [3]. Alzheimer’s dementia is also involved in inflammation and oxidative address 
and exhibits memory loss and cognitive dysfunction [4, 5].   
Two mechanisms underlying T2DM are insulin resistance and insufficient insulin secretion from 
pancreatic 𝛽-cells [4]. T2DM patients are unable to process insulin signaling correctly that lead 
to the insulin-resistant. In response to insulin resistance, pancreatic 𝛽-cells increase insulin 
production. However, when pancreatic 𝛽-cells gradually lose function; insulin production cannot 
be increased to maintain normal glucose levels.   The brain is a target organ for insulin [6]. 
Insulin signaling plays an important role in the organization and function of the brain and 
impaired insulin signaling induces an overactivation of GSK-3 kinase, increases tau 
phosphorylation, alters tau modification and causes neurofibrillary degeneration [7].  T2DM also 
suffer from mild to severe nervous system damage. Persistent blood glucose increases may 
impair blood flow to the brain [8].   
Prior work in ROSMP found an association of T2DM with incident Alzheimer’s dementia and 
rate of cognitive decline [9].  However, we did not find an association with Alzheimer’s disease 
(AD) pathology [10]. Rather, we found an association with cerebral infarcts. Other evidence 
from ROSMP continue to point to potential common mechanisms. For example, we found that 
brain insulin signaling was associated with AD pathology [11]. We also found interactions 
between GSKβ polymorphisms associated with β-amyloid deposition [12]. 
The current approaches to identifying several shared pathophysiology processes between 
Alzheimer’s dementia  and T2DM have several limitations. Firstly,  the most previous works 
have focused on identifying biological pathways underlying AD and T2MD. Few attempts to 
discover the role of dysregulated SNPs, gene expressions and methylations have been carried 
out. Secondly, the conventional evidences for linking AD and T2MD purely depend on the 
statistical association [13]. Numerous association studies strongly demonstrate that association 
analysis lacks power to discover the mechanisms of the diseases for the two major reasons. The 
first reason is that association and causation are different concepts. Association is to characterize 
the trend pattern between two variables, while causation between two variables is defined as 
independence between the distribution of cause and conditional distribution of the effect, given 
cause. There are three scenarios: (1) presence of both association and causation between two 
variables, (2) presence of association, while absence of causation and (3) presence of causation, 
while lack of association in causal analysis. If causation loci were searched only from association 
loci, many causation loci might be missed.  The second reason is that the widespread networks 
that are constructed in integrated omic analysis are undirected graphs. Using undirected graphs, 
we are unable to infer direct cause-effect relations and hence cannot discover chain of causal 
mechanism from genetic variation to diseases via gene expressions, epigenetic variation, 
physiological and phenotype variations.  Causal inference coupled with multiple omics, imaging, 
physiological and phenotypic data is an essential component for the discovery of disease 
mechanisms.  
It is time to develop a new generation of genetic analysis for shifting the current paradigm of 
genetic analysis from association analysis to deep causal inference and from genetic analysis 
alone to integrated causal genomic, epigenomic, and phenotypic data analysis for unraveling the 
mechanic link between AD and T2DM. To make the shift feasible, we need (1) to develop novel 
causal inference methods for genetic studies of AD and T2DM; (2) to develop unified 
frameworks for systematic casual analysis of integrated genomic, epigenomic, and clinical 
phenotype data and to infer multilevel omics causal networks for the discovery of common paths 
from genetic variants to AD and T2DM via methylations, gene expressions and multiple 
phenotypes.  The real dada set  ROSMAP [14, 15] will be used to valid the multilevel omics 
causal networks as a general framework for identifying shared causal paths between AD and 
T2DM and demonstrates that the proposed methods are capable of identifying the shared 
pathologic paths between AD and T2DM. A program for implementing the algorithm for 
construction of multilevel causal networks can be downloaded from our website 
https://sph.uth.edu/research/centers/hgc/xiong/software.htm. 
 
  
Methods 
ROSMAP Data 
The  data came from two longitudinal cohort studies of older persons, ROS that started in 1994 
and  enrolled Catholic nuns, priests, and brothers from more than 40 communities across United 
States,  and MAP that started in 1997 and  enrolled  participants with diverse backgrounds and 
socioeconomic status from continuous care retirement communities throughout northeastern 
Illinois, as well as from individual homes across the Chicago metropolitan area [34]. These two 
studies  are  managed by the same team of investigators. Structured, quantitative 
neuropathological examinations are performed at a single site. Therefore, the data can be 
combined in the analysis. Multi-layered omics datasets are generated from biospecimens donated 
by ROS and MAP participants, including genotypes, DNA methylation profiles and RNA-seq. 
The genotype data were generated by Affymetrix or the Illumina Omniquad express gene chips 
and were imputed using the 1000 Genomes Project data as reference. DNA methylation profiles 
were measured using  the Illumina Infinium HumanMethylation450 beadset.  RNA-seq data 
were generated using the Illumina HiSeq with 101bp paired-end reads.   Multiple phenotypes 
including clinical diagnosis, cognitive function, measures of lifestyle, behavior, and activity, 
chronic medical conditions and risk factors were measured.  A total of  432 individuals who 
simultaneously had genotype, RNA-seq, DNA methylation and some phenotypes were included 
in analysis. In the analysis, we considered 19 phenotypes and environments, two diseases (AD, 
T2DM), 299 pathways with RNA-Seq in KEGG pathway database, 20,242 methylation genes 
with 364,661 CpG sites, and 51, 060 genotyped genes with 5,711,541 SNPs ( 4,283,876 common 
snp, 1,427,665 rare snp). 
 
Genome-wide Causation Studies 
Unlike GWAS where we test the association of each variant across the genome with the disease, 
genome-wide causation studies (GWCS) is to test the causation of each variant across the 
genome to the disease. The additive noise models (ANMs) with discrete variables will be used 
for GWCS [27-30]. The procedures that use the ANMs for GWCS are summarized as follows 
[19].  
Procedures for Causal Genetic Analysis Using ANM: 
1. Fit the following nonlinear integer regression to the data. 
𝑌 = 𝑓(𝑋) + 𝑁𝑌. 
           Calculate the residuals ?̂?𝑌 = 𝑌 − 𝑓(𝑋). 
2. Fit the following nonlinear integer regression to the data. 
𝑋 = 𝑔(𝑌) + 𝑁𝑋. 
Calculate the residuals ?̂?𝑋 = 𝑋 − ?̂?(𝑌) . 
3. Test for independence. 
The contingence table and Fisher’s exact test can be used to test independence. Let the 
statistic for testing the independence between ?̂?𝑌 and 𝑋 as ∆𝑋→𝑌 and the statistic for 
testing the independence between ?̂?𝑋 and 𝑌 as ∆𝑌→𝑋. 
The null hypothesis for testing the causation of the variant is 
:0H  no causation between variables X and Y . 
The statistic for testing the causation between two X and Y  is defined as 
|| XYYXCT   .  
When CT  is large, the causation between genetic variant 𝑋 and disease status 𝑌 exists. When 
0CT , this indicates that no causal decision can be made. Since the distribution of the test 
statistic 𝑇𝐶  is difficult to calculate, P-value for testing the causation of the variant 𝑋 can be 
calculated by permutations.  
To improve the performance of causation analysis of rare variants, we first  calculate the 
functional principle component score (FPCS)of the rare variants within a gene [30] to summarize 
information of all rare variants within the gene . Then, the continuous FPCS are discreterized. 
Finally, the ANMs with discrete variables can be used to test causation of discreterized FPCS 
with the disease.  
Structural Equations for Construction of Causal Networks 
Directed graphical models and structural equations can be used as a tool to model the complex 
causal structures among variables [30]. A graphical model consists of nodes and edges. The 
nodes represent variables and edges represent the dependence structures among variables. A 
directed graphic model is defined as the graph in which all the inter-node connections have a 
direction visually denoted by an arrowhead. Directed acyclic graphics (DAGs) are defined as 
directed graphics with no cycles. In other words, we can never start at a node X , travel edges in 
the directions of the arrows and get back to the node X . A DAG with nodes encodes conditional 
dependence structure of the variables nYY ,...,1 . We define the parents of a node as the nodes 
pointing directly to it. The concept of parents provides an easy way to read off conditional 
independence from DAGs. 
Traditional regressions describe one-way or unidirectional relationships among variables in 
which the variables on the left sides of the equations are dependent variables and the variables on 
the right sides of the equations are explanatory variables or independent variables. The 
explanatory variables are used to predict the outcomes of the dependent variables. However, in 
many cases, there are two ways, or simultaneous relationships between the variables. Variables 
in some equations are response variables, but will be predictors in other equations.   The 
variables in equations may influence each other.  It is difficult to distinguish dependent variables 
and explanatory variables. The structural equation models (SEMs) are a powerful mathematic 
tool to describe such data generating mechanism and infer causal relationships among the 
variables. 
The SEMs classify variables into two class variables: endogenous and exogenous variables.  The 
jointly dependent variables that are determined in the model are called endogenous variables. 
The explanatory variables that are determined outside the model or predetermined are called 
exogenous variables.  In the genotype-phenotype networks, the phenotype variables such as 
BMI, cognitive function, working memory, are endogenous variables, age, sex, race, 
environments and genotypes are exogenous variables. In the genotype-expression networks, the 
gene expressions are endogenous variables and genotypes are exogenous variables. In the 
methylation-expression networks, gene expressions are endogenous variables and methylations 
are exogenous variables.  
We consider M endogenous variables. Assume that n individuals are sampled. We denote the 
n observations on the M endogenous variables by the matrix ],...,,[ 21 MyyyY  , where 
T
niii yyy ],...,[ 1  is a vector of collecting n observation of the endogenous variable i . 
Exogenous variables are denoted by ],...,[ 1 KxxX  where 
T
niii xxx ]...,[ ,1 .Similarly, random 
errors are denoted by ],,...,[ 1 MeeE  where we assume 0][ ieE and ni
T
ii IeeE
2][  for 
.,...,1 Mi  The linear structural equations for modeling relationships among variables can be 
written as: 
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where the  ’s and  ’s are the structural parameters of the system that are unknown.  Variables 
in the SEMs can be classified into two basic types of variables: observed variables that can be 
measured and the residual error variables that cannot be measured and represent all other 
unmodeled causes of the variables. Most observed variables are random. Some observed 
variables may be nonrandom or control variables (e. g. genotypes, drug dosages) whose values 
remain the same in repeated random sampling or might be manipulated by the experimenter. The 
observed variables will be further classified into exogenous variables, which lie outside the 
model, and endogenous variables, whose values are determined through joint interaction with 
other variables within the system. All nonrandom variables can be viewed as exogenous 
variables. The terms exogenous and endogenous are model specific. It may be that an exogenous 
variable in one model is endogenous in another. 
Traditionally, we often select one endogenous variable to appear on the left-hand side of the 
equation. Specifically, the i-th equation is  
𝑦𝑖 = 𝑦1𝛾1𝑖 + ⋯ + 𝑦𝑖−1𝛾𝑖−1𝑖 + 𝑦𝑖+1𝛾𝑖+1𝑖 + ⋯ + 𝑦𝑀𝛾𝑀𝑖 + 𝑥1𝛽1𝑖 + ⋯ + 𝑥𝐾𝛽𝐾𝑖 + 𝑒𝑖, (2) 
where ji is a path coefficient that measures the strength of the causal relationship from jy to iy , 
ki is a path coefficient from the exogenous variable to the endogenous variable which measure 
the causal effect of the exogenous variable 𝑥𝑘 on the endogenous variable iy .  The coefficients 
0ji  and 0ki imply the zero direct influence of jY  and 𝑥𝑘 on iY , respectively and are 
usually omitted from the equation. Therefore, equation (2) is reduced to 
iii
iiiiii
eW
eXYy

  
        (3) 
where 
iY is a vector of the endogenous variables after removing variable iy  , i is a vector of the 
path coefficients associated with iY , and 
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Multiplying by the matrix TX on both sides of equation (3),  we obtained 
i
T
ii
T
i
T eXWXyX  .       (4) 
Estimation of the parameters in the structural equations is rather complex. It involves many 
different estimation methods with varying statistical properties. We used two stage least squares 
(2SLS) method to estimate the parameters.  In general, the causal networks are sparse.  Using 
weighted least square and 
1l -norm penalization of equation (4), we can form the following 
optimization problem to estimate the structure of causal network: 
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The alternating direction method of multipliers (ADMM) and proximal methods can be used to 
estimate the parameters and structure of causal network [30, 67, 68]. 
Functional Structural Equation Models for Construction of Gene-based Causal Networks 
The SEMs carry out variant by variant analysis. However, the power of the traditional variant-
by-variant analytical tools for construction of causal networks with rare variants as exogenous 
variables will be limited. Large simulations have shown that combining information across 
multiple variants in a genomic region of analysis will greatly enhance the power to infer causal 
networks with rare variants as exogenous variables . To utilize multi-locus genetic information, 
we propose to use a genomic region or a gene as a unit in construction of causal networks and 
develop sparse structural functional equation models (SFEMs) for causal network analysis. 
We define a genotype function. Let t be a genomic position. Define a genotype function )(txi   of 
the i-th individual as 
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whereQ  and q  are two alleles of the marker at the genomic position t, )(tPQ and )(tPq are the 
frequencies of the alleles Q  and q , respectively. Suppose that we are interested in k  genomic 
regions or genes [ ],, jj ba denoted as kjT j ,...,2,1,  . We consider the following functional 
structural equation models (FSEMs): 
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where  Mikjtji ,...,1,,...,1),(  are genetic effect functions. 
Functional principal components (FPCs) are efficient summary statistics.  The FPCs 
simultaneously employs genetic information of the individual variants and correlation 
information (LD) among all variants. For each genomic region or gene, we use functional 
principal component analysis to calculate principal component function. Let N be the number of 
sampled individuals. We expand kjNntxnj ,...,2,1,,...,1),(  in each genomic region in terms 
of orthogonal principal component functions: 
,,...,1,)()(
1
kjttx
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l
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where jjl Llkjt ,...,1,,...,1),(  are the l -th principal component function in the j -th genomic 
region or gene and njl are the functional principal component scores of the n -th individual. 
Using the functional principal component expansion of )(txnj , we can transform the FSEMs (6) 
into the traditional multivariate SEMs (1). 
Integer Programming for Causal Network learning 
Given the dataset, learning causal networks is the task of finding  network structures  that best 
fits the data [22]. We used “score and search”  methods to  learn causal networks via maximizing 
the score metrics that characterize the causal networks. The “score and search” algorithms 
consist of two parts: (1) formulate objective function (global score for the whole network) using 
the score function for each node and (2) search algorithm.  
We collected all nodes with directed edges in the causal network into a DAG, denoted as 
),( EVG  . The score (objective function) for the DAG G was defined as  
𝑆𝑐𝑜𝑟𝑒 (𝐺) = ∑ 𝑆𝑐𝑜𝑟𝑒𝑗𝑗∈𝑉 (𝐺),           
where )(GjScore was a score for the node j  in the network. The )(GjScore was calculated as 
𝑓(∆𝑗) via solving the optimization problem (5).  Therefore, the total score can be decomposed 
into a sum of score for all nodes in the DAG. In addition, the )(GjScore is entirely determined 
by the parent set of the node j in G . A DAG can be encoded by the set },...,{ 1 pWWW  of 
parent variables for all nodes V in the graph G . We use ),( jWjC to denote a score function for 
the pair of node j and its parent set jW . Therefore, the total score for the DAG G  was given by  
),()( vVi WvCDC  . 
The learning task is to find a DAG that optimizes the global score )(DC over all possible DAGs 
D  or parent sets [22]: 
),(    min
, vDWViD
WvC
v
  . 
Integer linear  programming (ILP) was used as a search algorithm [22].  A DAG learning  was 
formulated as the ILP as follows. We define a variable )( vWx v   to indicate the presence or 
absence of the parent set vW  in the DAG. In other words, 1)(  vWx v if and only if it is the 
parent set for the node v . The parent set  vW  can be an empty set. The objective function for the 
ILP formulation of a DAG learning can be defined as  
   
p
v
J
j jj
v
v vv
vWxWvC
1 1
)(),( .       (7) 
The goal was to find a candidate parent set vW for each node v by optimizing the objective 
function in (7). It is clear that every DAG can be encoded by a zero-one indicator variable. 
However, any set of zero-one numbers may not encode a DAG. A set of linear constraints must 
be posted to make the set of indicator variables to represent a DAG. Without constraints all 
indicator variables for the parent sets will be equal to either zero or one. These solutions will not 
form a DAG. The constraints need to be imposed to ensure that the solutions encode a DAG. 
This constraint that is referred to as convexity constraint, can be expressed as  
  
j
j
j
I
i i
pjjWx
1
,...,1,1)( .        (8) 
The convexity constraints (8) can define a directed graph. However, the generated directed graph 
may have cycles. To eliminate a cycle, we need to impose the following constraint to ensure that 
any subset C of the nodes V in a DAG must contain at least one node that has no parent in the 
subset C  
∀𝐶 ⊆ ∑ ∑ 𝑥(𝑊 → 𝑗) ≥ 1𝑊:𝑊∩𝐶=∅𝑗∈𝐶 ,      (9) 
which is referred to as cluster-based constraints. Our goal is to find a candidate parent set jW for 
each node j by optimizing objective function (7) subject to the constraints (8) and (9).  
The branch and bound method is a popular algorithm ensured to find an optimal solution to the 
0-1 ILP problem [22] .  Let the LP solution represent “solution of the current linear relaxation”. 
The basic idea of the branch and bound method is to successively divide the ILP problem into 
smaller problems that are easy to solve and reduce the search space. Briefly, the branch and 
bound algorithm is summarized as follows. Step 1: Let xˆ be the LP solution. Step 2: if there are, 
valid constraints not satisfied by xˆ  add them and go to Step 1; otherwise if the solution xˆ is an 
integer then stop, the current problem is solved; otherwise branch on a variable with a non-
integer part in xˆ to generate two new sub-IP problems. We then again use branch and bound 
algorithms to solve two sub-ILP problems [22].  
Multilevel Causal Networks 
Multilevel causal omic networks integrated genotype subnetworks, methylation subnetworks, 
gene expression subnetworks,  the intermediate phenotype subnetworks and multiple disease 
subnetworks into a single connected multilevel genotype-disease networks to reveal the deep 
causal chain of mechanisms underlying the diseases [30]. ILP  was extended from a single causal 
network estimation to joint multiple causal network estimations to integrate genomic, 
epigenomic and phenotype data.  
For the convenience of discussion, consider M gene expression variables MYY ,...,1 , Q  
methylation variables QZZ ,...,1 , and K  genotype variables KXX ,...,1 . Let )(dpaD be the parent 
set of the node d including gene expression, methylation and genotype variables.  Consider three 
types of SEMs. First, we consider a general SEM model for the gene expression: 
     )( )()( )()()( dpaq dpaj djdjqdqdpai idid D DD XfZfYfY  ,  𝑑 = 1, … , 𝑀, (10) 
and 
   )()( )()( qpam qmqmqpal lqlq QQ XfZfZ  , 𝑞 = 1, … , 𝑄,   (11) 
where 
df and qf are linear functions  from RR
Dpa ||  and RR Q
pa

||
, respectively,  and the 
errors 
d  and q are independent , following  distributions dP  and qP , respectively.  Equation 
(10) define a causal network that connects gene expressions, methylations and genotypes. 
Equation (11) define a causal network that connects methylations and genotypes.  
Integer Programming as a General Framework for Joint Estimation of Multiple Causal 
Networks 
We collected multiple types of data: genotype, gene expression, methylation, and phenotype and 
disease data. We wanted to estimate multiple causal networks with different types of data.  
The scores of the nodes dY  and qZ  were, respectively, given by 
d
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where matrices 
i
YD and 
l
ZD  corresponded to the parent sets diW and qlW . 
Let EV be the set of nodes in the gene expression network and MV be the set of nodes in the 
methylation network. Let EC be a subset of nodes in EV  and MC be a subset of nodes in MV .  A 
joint expression and methylation causal network can be formulated as the following ILP: 
)(),()(),(   Min       
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Using branch and bound and other methods for solving the ILP, we can solve the ILP problem 
(14) to obtain the best joint causal genotype-methylation-expression and genotype-methylation 
network fitting the data. 
Summary Statistics for Representation of Groups of Gene Expressions 
Generalized low rank models were used to segment (cluster) the data. Principal component 
analysis (PCA) was used to  reduce data dimensions. The PCs were used to summarize the gene 
expression data in pathways  and clusters [69].  
Results 
Shared genetic loci underlying AD and T2DM. 
AD and T2DM result from the interplay of DNA sequence variation and nongenetic factors 
acting through molecular networks [16-18].  Their etiology is complex with multiple steps 
between genes and phenotypes. Neither traditional GWAS, nor classical multi-omics analysis 
can identify the causal paths from genetic variants to diseases because not all these analyses can 
identify directed paths from genetic variants to diseases through environments, methylations, 
gene expressions, and phenotypes. To overcome these limitations, we develop a novel general 
framework for identifying all possible causal paths from genetic variants to diseases. The 
framework consists of three steps. The first step is to perform genome-wide causation studies 
(GWCS) where we test causation of each SNP across the genome to the disease. The additive 
noise model (ANM) with discrete variants will be used to test for causation [19] (Methods). We 
focused on the rare variants in the paper. The second step is to use integer programming (IP) and 
various modern causal models [20-22] (Methods) for inferring multilevel genome-wide omic 
causal networks that integrate genotype subnetworks, environmental subnetworks, methylation 
subnetworks, gene regulatory subnetworks, intermediate phenotype subnetworks and multiple 
disease subnetworks  into a single connected multilevel genotype-disease network as shown in 
Figure 1. The third step is to augment graph theoretical approaches with approximations for 
developing  efficient search algorithms that discover all possible paths starting from the genetic 
variant node directed to the disease node, including classical Depth First Search (DFS) and 
Breadth First Search (BFS) algorithms [23-26].  
There are two ways to identify shared dysfunctional genes (SNPs) between AD and T2DM. One 
way is to use ANM with discrete variables and functional data analysis to conduct genome-wide 
causation analysis [27-30] for unravelling the direct connections between gene nodes and disease 
nodes  to identify the shared dysfunctional genes  between AD and T2DM.  
Another way is to search the paths from the gene nodes to AD and T2DM in multilevel causal 
omics networks. 
Association and causation are different concepts.  Association between two variables is often 
characterized by dependence between two variables. Causation is a connection of phenomena 
where one variable acts or intervenes on another variables and leads to its changes.  Therefore,  
the key component of causation  is the generation and determination of values of one variable by 
another. The  mechanism of causation  is related to the transference of matter, motion and 
information. Causation is universe. It is a part of universe connection. It is well known that 
nature consists of autonomous and independent causal generating process modules. These 
modules will not influence each other [29, 31]. In other words, while output of one module may 
inform or influence input of another module, the events between modules are independent. In the 
probabilistic language, mechanism is often represented by conditional distribution. Independent 
mechanism states that “the conditional distribution of each variable given its causes (i.e., its 
mechanism) does not inform or influence the other conditional distributions” [29]. In GWCS, we 
only consider two variables. In this case, independence of cause and mechanism (ICM) indicates 
that the conditional distribution of the effect given its cause is independent of distribution of 
cause.  Consider the genetic analysis of alleles (𝐴) with a disease allele 𝐴    a normal allele 𝑎   
and with the disease(𝐷) (disease 𝐷  and normal 𝑑 ).  The joint density function 𝑃(𝑎, 𝑑) can be 
decomposed into 
𝑃(𝐴, 𝐷) = 𝑃(𝐴)𝑃(𝐷|𝐴) 
                                                                        = 𝑃(𝐷)𝑃(𝐴|𝐷). 
In the association analysis, we assess whether 𝐴 is independent of 𝐷 or not. The relationship 
between 𝐴 and 𝐷 is symmetric. However, in causal analysis, causations 𝐴 → 𝐷 and 𝐷 → 𝐴 are 
different. They are asymmetric. Assessing causation is to consider the effect of intervention. 
Causation 𝐴 → 𝐷 indicates that the effect of 𝐴 is to give rise to disease. However, disease status 
𝐷 will not generate allele 𝐴. Suppose that locus 𝐴 is disease locus and 𝐴 → 𝐷. If we change the 
allele 𝑎 to allele 𝐴, then we assume that biological mechanism 𝑃(𝐷|𝐴) responsible for giving 
rise to disease. This would hold true independent of the distribution (frequencies)_of allele 𝐴. If 
the locus A is disease locus, we can find that the distributions (frequencies) of allele 𝐴 in two 
different populations are different, but the mechanism 𝑃(𝐷|𝐴) would apply in two population.  
The conditional probability 𝑃(𝐷|𝐴) can also be viewed as penetrance of the allele. The marginal 
distribution 𝑃(𝐴) and conditional distribution 𝑃(𝐷|𝐴) contain no information about each other.  
Both continuous and discrete ANMs satisfy the ICM and will be used for GWCS.,     The 
proposed method for genome-wide causation analysis and inferring multilevel causal genotype-
methylation-expression-phenotype-disease network was applied to the ROSMAP  dataset [34] 
with  432 individuals, 19 phenotypes and environments, two diseases (AD, T2DM), 299 
pathways with RNA-Seq in KEGG pathway database, 20,242 methylation genes with 364,661 
CpG sites, and 51, 060 genotyped genes with 5,711,541 SNPs ( 4,283,876 common snp, 
1,427,665 rare snp ) (imputed by 1000 Gnome Data). The inferred genotype-expression-
methylation-phenotype-disease network consisted of 2,814 nodes and 22,184 edges where the 
edges were presented in the network if the path coefficients were significantly from zero with P-
values < 0.05.  
Table 1. The number of genes connected to AD and T2DM.  
 
  To T2DM 
    
Directly 
Connected 
Indirectly 
Connected 
Both Directly and 
Indirectly Connected 
Not 
Connected 
To 
AD 
Directly Connected 5     13 
Indirectly Connected  682 13  
Both Directly and 
Indirectly Connected 
 20 8  
Not Connected 17       
 
There were two ways to connect a gene (or SNP) to AD (T2DM). If a gene (or SNP) showed 
causation to AD (T2DM)  by statistical causal test,  then the gene (SNP) was directly connected 
to AD (T2DM) in the causal network. Such gene (SNP) was called AD (T2DM) directly 
connected gene (SNP). We may observe the connection between a gene (SNP) and AD (T2DM) 
via multiple edges (paths) in the constructed multilevel causal network.  Then, the gene (SNP) 
that was indirectly connected to AD (T2DM) via paths in the multilevel causal network  was 
called  AD (T2DM) indirectly connected gene (SNP). The number of AD and T2DM directly 
connected or indirectly connected genes was summarized in Table 1.  The total number of genes 
connected to both AD and T2DM including directly connected and indirectly connected was 759.  
The genes that were both directly and indirectly connected to both AD and T2DM were 
summarized in Table S1. The genes that were indirectly connected to AD and both directly and 
indirectly connected to  T2DM were listed in Table S2.  Similarly, the genes that were both 
directly and indirectly connected to AD and indirectly connected to T2DM were summarized in 
Table S3. 
We also tested causation of 299 pathways in the KEGG pathway database to AD and T2DM 
(Described in detail in the Methods section). The results were summarized as follows. The 
number of pathways that were directly connected to both AD and T2DM was 16; the number of  
pathways that were directly connected to AD and indirectly connected to T2DM was 17; the 
number of pathways that were directly connected to T2DM and indirectly connected to AD was 
18,  the number of pathways that were indirectly connected to both AD and T2DM was 114; the 
number of pathways that were directly connected to AD and not connected to T2DM was 6; the 
number of pathways that were not connected to AD and directly connected to T2DM was 2.  
Then, we investigated shared gene expressions via multilevel causal networks. We summarized 
the results as follows. The number of expression genes that were directly connected to both AD 
and T2DM was two genes: GRMD1B, RP1-111D6.3, the number of expression genes  that were 
directly connected to AD, but not directly connected to T2DM was 19 (P-value < 10−4, Table 
S4) and the number of expression genes that were directly connected to T2DM, but not directly 
connected to AD  was 7 (P-value < 10−4, Table S5).  The number of expression genes that were 
indirectly connected to both AD and T2DM was 725.   
Similarly, we can study shared methylation via multilevel causal networks.  The number of 
methylated sites/ genes that were directly connected to AD, but not directly connected to T2DM 
was 17 (Table S6) and the number of methylated sites/genes that were directly connected to 
T2DM, but not directly connected to AD was 27 (Table S7).  The number of methylated 
sites/genes that were indirectly connected to both AD and T2DM was  117 (Table S8). 
The number of phenotypes that were directly connected to both AD and T2DM was six (Age, 
CHL, HDL ratio, LDL, Semantic memory and working memory).   
Shared CREBBP, MAPK and PI3K-AKT pathways between AD and T2DM 
Binding of transcription factors to the cyclic Adenosine Monophosphate (cAMP) response 
element (CRE) regulates the activity of RNA polymerase. cAMP Response Element binding 
protein (CREB) is a cellular transcription factor that binds the CRE [32]. CREB-binding protein 
(CREBBP) and CREB together mediate the conversion of short-term memory to long-term 
memory and alternate the activity of the β-amyloid (Aβ) peptide, which in turn regulates 
hippocampal-dependent synaptic plasticity [33, 34]. Cognitive function such as working memory 
is involved in insulin signaling dysfunction and blood glucose levels. It was reported that 
working memory is linked with T2MD [35-37].  
To assess whether CREBBP is a common genetic factor of AD and T2DM, and how CREBBP 
mediates the development of AD and T2DM, we searched the all possible paths from gene 
CREBBP to AD and T2DM in the inferred multilevel causal network. The results were shown in 
Figure 2. Figure 2A plotted the path from CREBBP to AD and T2DM via MAPK and PI3K-
AKT signaling pathways.  The genes in the MAPK and PI3K-AKT signaling pathways, 
CREBBP, episodic memory, MMSE, AD and T2DM were then used to further infer causal 
networks using SEMs and IP. The inferred causal network was shown in Figure 2B.  From 
Figure 2B we observed a path from CREBBP to AD and T2DM via gene connections: 
𝐶𝑅𝐸𝐵𝐵𝑃 → 𝐶𝐵𝐿 → 𝑀𝐴𝑃2𝐾4 → 𝑀𝐴𝑃𝐾8 → 𝑀𝐴𝑃𝐾1 → 𝑃𝐼𝐾3𝐶𝐴.  MAPK and PI3K-AKT 
pathways play critical roles in memory.  
Shared TTC3, FoxO, MAPK, and PI3K-AKT Pathways between AD and T2DM 
Next we presented an example to illustrate shared causal paths that started a gene directly 
connected to AD and indirectly connected to T2DM.  The tetratricopeptide repeat domain 3 
(TTC3) gene was an AD causing gene (P-value for causation of AD  < 0.0001), but not directly 
connected to T2DM (P-value for causation of T2DM =0.47). TTC3 is associated with 
differentiation of neurons [38]. It is reported that a rare TTC3 variant is related with AD [39]. 
The TTC3–RhoA pathway could be a key determinant of the neuronal development, resulting in 
detrimental effects on the normal differentiation program [40]. Rho regulates the activation of 
MAPK pathway [41]. The Forkhead box O (FoxO) transcription factors  that affect nervous 
system amyloid (Aβ) production, are implicated in the regulation of cell apoptosis and survival, 
and accelerate the progression of degenerative disease. FoxO pathway is involved in the 
PI3K/Akt and mitogen-activated protein kinase (MAPK) pathways in neuronal apoptosis in the 
brain.  
FoxOs also can offer protection in the nervous system, reduce toxic intracellular protein 
accumulations and have potential to limit Aβ toxicity [42, 43, 34]. Akt-FoxO that suppresses 
TLR4 signaling in Human Leukocytes is implicated in the development of T2DM [44]. There are 
increasing evidences that  PI3K/AKT pathway are implicated  in the development of T2DM [45, 
46].  
Again, we used the  DFS algorithm to search the causal paths  from multilevel causal networks. 
The causal paths from TTC3 to AD and T2DM were shown in Figure 3. The paths from  MAPK 
and PI3K-AKT pathway to AD and T2DM were the same as that in Figure 2. The genes in  the 
FoxO, MAPK and PI3K-AKT signaling pathways, TTC3, and episodic memory, MMSE, weight, 
AD and T2DM were then used to further infer causal networks using SEMs and IP. The structure 
of the inferred network was shown in Figure 3B. There were a large number of causal paths from 
TTC3 to either AD or T2DM. The shared common causal paths were 𝑇𝑇𝐶3 → 𝑁𝐿𝐾 →
𝐶𝐴𝐶𝑁𝐴2𝐷1 → 𝐶𝑁𝐶𝑁𝐺3 → 𝐹𝑂𝑋𝑂1 → 𝐶𝐶𝑁𝐸1 → 𝐶𝑌𝐶𝑆 → 𝑀𝐴𝑃𝐾1 → 𝑃𝐼𝐾3𝐶𝐴  and 𝑇𝑇𝐶3 →
𝑁𝐿𝐾 → 𝑃𝐿𝐾2 → 𝑀𝐴𝑃𝐾8 → 𝑀𝐴𝑃𝐾1 → 𝑀𝐴𝑃𝐾1 → 𝑃𝐼𝐾3𝐶𝐴. 
Shared Morphine Addiction and Neuroactive Ligand Receptor Interaction Pathways 
Morphine addiction has neurotoxic effects and damages to the brain regions that function for 
learning, memory and emotions [47]. High dose of morphine may increase risk to  T2DM [48]. It 
is also reported that neuroactive ligand receptor interaction pathway is associated with both AD 
and T2DM [49].   
Searching the causal paths from gene HNF4G to AD and T2DM via the multilevel causal 
networks using the DFS algorithm, we found that HNF4G was indirectly connected to AD and 
T2DM. In addition to shared MAPK and PI3K-AKT pathways between AD and T2DM which 
were discussed in the previous sections,  we observed shared two new pathways between AD and 
T2DM: morphine addiction and neuroactive ligand receptor interaction pathways as shown in 
Figure S1A. The structure of the inferred network that consisted of shared morphine addiction 
and neuroactive ligand receptor interaction pathways between AD and T2DM was shown in 
Figure S1B. There were more than 10 shared causal paths. We observed two shared major causal 
paths: (1) 𝐻𝑁𝐹4𝐺 → 𝑁𝐿𝐾 → 𝑃𝐿𝐾2 → 𝑀𝐴𝑃𝐾8 → 𝑀𝐴𝑃𝐾1 → 𝑃𝐼𝐾3𝐶𝐴 → 𝐴𝐾𝑇1 amd  (2) 
𝐻𝑁𝐹4𝐺 → 𝑁𝐿𝐾 → 𝐺𝑁𝐺𝑇2 → 𝑃𝐿𝐶𝐵2 → 𝑃𝐿𝐶𝐵1 → 𝐴𝐷𝑅𝐵1.  
Shared Fatty Acid Biosynthesis and Primary Bile Acid Biosynthesis Pathways  
Brain function such as intelligence, memory, behavior and concentration are all influenced by  
brain nutrition [50]. Omega-3 fatty acids affect  the fluidity of brain cell membranes, 
neurotransmitter synthesis and signal transmission and are implicated in AD [51, 52]. Bile acids 
are involved in cell signaling and immune function. It acts as potent inhibitors of apoptosis and  
regulates transcriptional and post-transcriptional events that affect mitochondrial function in 
neurons [53].  A trend of increased bile acids in AD has been observed [54]. Fatty acid 
utilization induces insulin resistance [55]. Bile acids are signal molecules and play an important 
role in regulating metabolism and inflammation. The abnormal bile acids are correlated with 
changes in insulin secretion, which lead to T2DM [56, 57]. The amyloid precursor protein (APP) 
is a transmembrane protein. The aggregated amyloid-β (Aβ) peptides are generated by sequential 
proteolytic processing of the APP. Accumulation of Aβ and the APP play an important role in 
regulating lipid homeostasis including fatty acids, which finally affect the development of AD 
[58].   
Our data also provided evidence to show that fatty acid biosynthesis and primary bile acid 
biosynthesis pathways were shared pathways between AD and T2DM. Search the multilevel 
causal networks from APP to AD and T2DM using the  DFS algorithm, we identified the shared 
causal paths from APP to both AD and T2DM, shown in Figure 4A. There were two shared 
causal paths between AD and T2DM: 𝐴𝑃𝑃 →  𝑛𝑒𝑢𝑟𝑜𝑎𝑐𝑡𝑖𝑣𝑒 𝑙𝑖𝑔𝑎𝑛𝑑 𝑟𝑒𝑐𝑒𝑝𝑡𝑜𝑟 𝑖𝑛𝑡𝑒𝑟𝑎𝑐𝑡𝑖𝑜𝑛 and 
𝐴𝑃𝑃 → 𝑓𝑎𝑡𝑡𝑦 𝑎𝑐𝑖𝑑 𝑏𝑖𝑜𝑠𝑦𝑛𝑡ℎ𝑒𝑠𝑖𝑠 → 𝑝𝑟𝑖𝑚𝑎𝑟𝑦 𝑏𝑖𝑙𝑒 𝑎𝑐𝑖𝑑 𝑏𝑖𝑜𝑠𝑦𝑛𝑡ℎ𝑒𝑠𝑖𝑠. Neuroactive ligand 
receptor interaction pathway was discussed in the previous section.  
Next we presented the causal network structure of the shared genes between AD and T2DM in 
the two shared causal paths in Figure 4B. We observed two major shared paths from APP to AD 
and T2DM. One path was 𝐴𝑃𝑃 → 𝐴𝐶𝑆𝐿4 → 𝐴𝐶𝐴𝐶𝐴 → 𝑁𝑈𝐷𝑇9 → 𝐶𝑀𝐶1 → 𝑃𝑇𝑃𝐿𝐴𝐷1 →
𝐶𝑌𝑃781 → 𝐶𝑌𝑃46𝐴1 → 𝑤𝑜𝑟𝑘𝑖𝑛𝑔 𝑚𝑒𝑚𝑜𝑟𝑦 (𝑜𝑟 𝐶𝑌𝑃781 → 𝐴𝑀𝐴𝐶𝐴 → 𝑤𝑜𝑟𝑘𝑖𝑛𝑔 𝑚𝑒𝑚𝑜𝑟𝑦). 
Another causal path was  𝐴𝑃𝑃 → 𝐹2𝑅𝐿3 → 𝑃𝐼𝐾3𝑅3 (𝑜𝑟 𝐹2𝑅𝐿3 → 𝑆1𝑃𝑅3 → 𝑃𝐼𝐾3𝑅3).   
To further illustrate the validity of the inferred causal paths, we presented Figure S2 that showed 
the average levels of expression of the genes  in Figure 4 for  AD, T2DM and normal 
individuals.  From Figure 4,  Figures S2 and S3, we can observed that  the genes  along the path 
𝐴𝑃𝑃 → 𝐹2𝑅𝐿3 → 𝑃𝐼𝐾3𝑅3 (𝑜𝑟 𝐹2𝑅𝐿3 → 𝑆1𝑃𝑅3 → 𝑃𝐼𝐾3𝑅3) of the individuals with AD were 
over expressed, and the genes along the path 𝐴𝑃𝑃 → 𝐴𝐶𝑆𝐿4 → 𝐴𝐶𝐴𝐶𝐴 → 𝑁𝑈𝐷𝑇9 → 𝐶𝑀𝐶1 →
𝑃𝑇𝑃𝐿𝐴𝐷1 → 𝐶𝑌𝑃781 → 𝐶𝑌𝑃46𝐴1 → 𝑤𝑜𝑟𝑘𝑖𝑛𝑔 𝑚𝑒𝑚𝑜𝑟𝑦 (𝑜𝑟 𝐶𝑌𝑃781 → 𝐴𝑀𝐴𝐶𝐴 →
𝑤𝑜𝑟𝑘𝑖𝑛𝑔 𝑚𝑒𝑚𝑜𝑟𝑦) of the individuals with AD were under expressed. Genetic variation in gene 
APP either regulated over expressed genes or regulated under expressed genes. Both of them 
caused AD.  For the individuals with T2DM, the majority of gene expressions along the causal 
paths from APP to T2DM which were regulated by  genetic variation in gene APP was under 
expressed. 
Shared  Methylated Genes POU3F2, KIF4B and TNSL3, and Dopaminergic Synapse and 
AMPK Pathways 
In this section, we illustrate how a shared gene regulates three shared gene methylations, which 
in turn regulate the shared pathways. Emerging evidences indicate that methylation alternations 
to  DNA of the brain are linked to Alzheimer’s disease [62, 63]. DNA methylation also plays an 
important role in the pathogenesis of T2DM [63, 64]. In order to better understand the etiology 
of AD and T2DM, we jointly investigated the genetic variants, DNA methylation and gene 
expression profiles, multiple phenotypes, AD and T2DM using causal inference pipelines. We 
found that gene POU3F2 regulated methylations of POU3F2, KIF4B and TMSL3. Alternations 
in  methylation of three genes directly caused the development of AD and T2DM. Furthermore, 
methylation levels of three genes regulated gene expressions in dopaminergic synapse and 
AMPK pathways, which in turn caused AD and T2DM via CHL/HDL Ratio (Figure 5A). Recent 
advance revealed that Alterations of the dopaminergic system contributes to memory and reward 
dysfunction and the dopaminergic system may well be involved in the occurrence of AD [59, 
60]. Recent studies also unravel that the brain damage in AD is linked to an over-activation of 
AMPK, which leads to the loss of the ability of neurons to grow axons and the modification of 
the tau proteins resulting in tangles of tau [65].  The AMPK functions as a key energy sensor.   
AMPK signaling elicits insulin-sensitizing effects and  may be implicated in stimulating glucose 
up taking in skeletal muscles, fatty acid oxidation in adipose (and other) tissues [66]. Our results 
showed that genetic variation in  gene POU3F2 regulated gene expressions in dopaminergic 
synapse and AMPK pathways via methylations of POU3F2, KIF4B and TMSL3, which in turn 
influences  CHL/HDL Ration, and finally led to AD and T2DM (Figure 5A). 
Again, we presented the causal network structure of the shared genes between AD and T2DM in 
the two shared dopaminergic synapse and AMPK pathways in Figure 5B. There were multiple 
shared directed paths from POU3F2 to AD and T2DM. A major shared directed path: 
𝑚: 𝑃𝑂𝑈3𝐹2 → 𝑚: 𝐿𝑂𝐶644649 → 𝐾𝐷𝑀5𝐶 → 𝑃𝐷𝑃𝐾2 → 𝑋𝑃𝐴 → 𝑀𝐾3𝑅2 → 𝐸𝐿𝐾1 →
𝐴𝐷 (𝑜𝑟 → 𝐶𝐻𝐿 → 𝑇2𝐷𝑀).  
  
Discussion 
This paper addresses several issues for uncovering causal paths shared between AD and T2DM. 
The first issue is to shift the current paradigm of genetic analysis from association analysis to 
deep causal inference for uncovering the shared mechanisms between AD and T2DM. The 
current paradigm for discovering mechanisms of diseases is association analysis. There is 
increasing recognition that a large proportion of association signals are not causal signals and 
causal signals may not be association signals. A large number of causal signals cannot be derived 
from set of association signals. Only searching causal signals from association analysis, a large 
proportion of causal signals will be missing.  Therefore, the ANMs were  developed as practical 
causal inference methods to identify the genetic variants that cause disease.  
Second issue is to shift the current paradigm of genetic analysis from genetic analysis alone to 
integrated causal genomic, epigenomic, transcriptional and phenotypic data analysis for 
unraveling the mechanisms of AD and T2DM. The widespread existing omics networks that are 
constructed in integrated multistep analysis of omics are undirected graphs. Using undirected 
graphs, we are unable to infer direct cause-effect relations among diversified types of variables at 
multilevel and hence cannot discover chain of causal mechanism from genetic variation to 
diseases via omics. In this paper, we develop novel statistical methods for multilevel causal 
omics network construction and provide pipelines for uncovering shared causal paths between 
AD and T2DM via gene expressions, DNA methylations, environments and multiple phenotypes.  
The third issue is to develop algorithms that can automatically search the causal paths from 
genetic variants to diseases. The size of multilevel causal omics network is large. The number of 
nodes of such networks can reach ten thousands. The number of causal paths is huge. Manually 
searching causal paths from large causal networks is infeasible. To meet the challenge of 
searching causal paths from large causal networks, we develop computer representation of large 
causal networks and algorithms for searching the causal paths.  
  
Conclusion 
     The results of application of the proposed pipelines for identifying causal paths to real data 
analysis of AD and T2DM provided strong evidence to support the link between AD and T2DM 
and unraveled causal mechanism to explain this link. We identified the shared causal genes, gene 
expressions, DNA methylations and pathways between AD and T2DM. Some of them can be 
supported by literature and some of them are new. We identified an extremely large number of 
shared causal paths from genetic variants to both AD and T2DM via DNA methylation, gene 
expressions and phenotypes. This deep knowledge that uncovered the large number of causal 
mechanisms of AD and T2DM had profound implication in prevention and treatments of AD and 
T2DM. This explained why the drugs that were based on inhibition or activation of limited 
number of paths often failed simply because these limited number of paths cannot cover all 
causal paths to the diseases. Finally, the empirical evidence that the AD and T2DM shared a 
large number of causal genes, gene expressions, methylations and pathways supported 
hypothesis that AD can be considered as “type 3 diabetes”.  
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Figure 
Figure 1. Scheme of multilevel omic networks. 
 
 
 
 
 
 
 
 
Figure 2. (A) Shared CREBBP, MAPK and PI3K-AKT pathways between  AD and T2DM; (B) 
Shared causal subnetwork structure from CREBBP to AD and T2DM. 
 
 
 
Figure 3. (A)Shared TTC3, FoxO, MAPK, and PI3K-AKT Pathways between AD and T2DM; 
(B) Shared causal subnetwork structure from TTC3 to AD and T2DM. 
 
 
Figure 4. (A) Shared APP, Fatty Acid Biosynthesis and Primary Bile Acid Biosynthesis 
Pathways  between AD and T2DM; (B) Shared causal subnetwork structure from APP to AD 
and T2DM. 
 
Figure 5. (A) Shared  Methylated Genes POU3F2, KIF4B and TNSL3, and Dopaminergic 
Synapse and AMPK Pathways between AD and T2DM; (B) Shared causal subnetwork structure 
from POU3F2 to AD and T2DM. 
 
 
Supplementary Figure 
Figure S1. (A) Shared morphine addiction and neuroactive ligand receptor interaction pathways 
between AD and T2DM; (B) Shared causal subnetwork structure from HNF4G to AD and 
T2DM. 
 
 
 
 
 
 
 
 
 
 
 
Figure S2. Average expression levels of genes in Figure 4 for AD, T2DM and normal 
individuals where gene expression levels were normalized. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S3. (A) Two major causal paths from APP to AD and T2DM in Figure 4; (B) Differential 
expressions of the genes along two major causal paths in (A) between AD and normal 
individuals where the nodes in red color represented over expressed genes, the nodes in green 
color represented the under expressed genes and the nodes in the grey color represented the 
genes showing no differential expressions; (C) Differential expressions of the genes along two 
major causal paths in (A) between T2DM and normal individuals where the nodes in red color 
represented over expressed genes, the nodes in green color represented the under expressed 
genes and the nodes in the grey color represented the genes showing no differential expressions. 
 
 
 
 
Supplementary Table 
Table S1 
  
Gene 
T2DM AD 
Causation Association Causation Association 
GTF2H2C <E-06 0.000156 <E-06 0.075045 
NAIP <E-06 0.000785 <E-06 0.057792 
RN7SL9P <E-06 0.000156 <E-06 0.075045 
RP11-497H16.5 <E-06 0.001671 <E-06 0.182268 
RP11-497H16.6 <E-06 0.000334 <E-06 0.200074 
SERF1B <E-06 0.000447 <E-06 0.163819 
SMN2 <E-06 0.000447 <E-06 0.163819 
ZNF658B <E-06 0.867831 <E-06 0.102522 
 
 
 
 
Table S2 
  
  
AD T2DM 
Causation Association Causation Association 
LINC01123 <E-06 0.209055802 <E-06 0.007821734 
ZBTB45P1 <E-06 0.209055802 <E-06 0.007821734 
GTF2H2C <E-06 0.045337348 <E-06 0.000155933 
NAIP <E-06 0.023560082 <E-06 0.000785176 
RN7SL9P <E-06 0.075045141 <E-06 0.000155933 
RP11-497H16.5 <E-06 0.027245868 <E-06 0.001670784 
RP11-497H16.6 <E-06 0.106195835 <E-06 0.000334017 
SERF1B <E-06 0.017756029 <E-06 0.000446698 
SMN2 <E-06 0.017756029 <E-06 0.000446698 
RN7SL763P <E-06 0.242608501 <E-06 0.887587122 
RANP9 <E-06 0.153098533 <E-06 0.206418787 
ZNF658B <E-06 0.006744952 <E-06 0.203671552 
AC132872.2 <E-06 0.118907963 <E-06 0.047484691 
 
 
 
Table S3 
  
  
AD T2DM 
Causation Association Causation Association 
IGKV6D-21 <E-06 0.00936 
 
0.00838 
RN7SL632P <E-06 0.00053 
 
0.10824 
CDH18 <E-06 0.00736 
 
0.11987 
HLA-DRB5 <E-06 0.01958 
 
0.01317 
RPL3P2 <E-06 0.00391 
 
0.05737 
FAM74A6 <E-06 0.00256 
 
0.17522 
RNU6-156P <E-06 0.00209 
 
0.00086 
RP11-15J10.1 <E-06 0.00876 
 
0.01246 
RP11-262H14.4 <E-06 0.00173 
 
0.01412 
RP11-318K12.2 <E-06 0.0031 
 
0.00086 
RNU6-702P <E-06 0.01116 
 
0.26546 
AL021920.1 <E-06 0.00529 
 
0.10803 
AL590452.1 <E-06 0.0034 
 
0.01512 
EIF1AXP1 <E-06 0.00529 
 
0.10803 
FAM231B <E-06 0.00187 
 
0.28261 
PRAMEF11 <E-06 0.00122 
 
0.07388 
RP5-845O24.8 <E-06 0.00122 
 
0.07388 
TTC3 <E-06 0.0102 
 
0.01343 
AC009237.16 <E-06 0.0024 
 
0.17164 
AC009237.17 <E-06 0.0024 
 
0.17164 
 
 
 
 
 
 
 
 
 
 
 
Table S4 
  
  
Gene 
P-value 
Causation Association 
AD T2DM AD T2DM 
PLA2G15 <0.0001 0.6633 0.0012 0.7645 
GRPEL2 <0.0001 0.3611 0.0026 0.9894 
TCEAL6 <0.0001 0.7324 0.0001 0.3729 
C19orf71 <0.0001 0.8063 0.0002 0.4285 
GRTP1 <0.0001 0.7326 0.0004 0.4044 
CTC-471C19.1 <0.0001 0.9039 <0.0001 0.8677 
GAP43 <0.0001 0.413 0.0001 0.2183 
NTNG1 <0.0001 0.2216 <0.0001 0.298 
BIN1 <0.0001 0.9583 0.4087 0.809 
ZNF683 <0.0001 0.5699 0.0098 0.391 
PIGS <0.0001 0.361 0.0624 0.7423 
MRPS18A <0.0001 0.4478 0.0004 0.8081 
PRKCD 0.0001 0.5847 0.0006 0.0814 
FNDC5 0.0001 0.8283 0.0000 0.9253 
SLC7A14 0.0001 0.9696 0.0101 0.7183 
GRAMD1B 0.0001 0.0005 0.0171 0.6413 
USP12 0.0001 0.5937 0.041 0.0269 
DHRS7 0.0001 0.9111 0.0571 0.4734 
OAZ1 0.0001 0.7556 0.0089 0.6632 
 
 
Table S5 
Gene  
 
P-value 
Causation Association 
T2DM AD T2DM AD 
GRN <0.0001  0.3019 <0.0001 0.3037 
ATP1B3 <0.0001 0.3848 <0.0001 0.3358 
CTD-3065J16.6 <0.0001 0.5351 0.4403 0.2133 
BX571672.1 <0.0001 0.587 0.5182 0.3088 
SLC25A35 <0.0001 0.7881 0.6975 0.3619 
PRR12 <0.0001 0.9786 0.3704 0.281 
AOC3 <0.0001 0.9936 0.1873 0.0678 
 
Table S6 
  
Methylated Gene 
 P-value  
 Causation   Association  
 EMX2OS   < 1e-4  0.1973 
 PIPOX   < 1e-4  0.6245 
 DHX8   < 1e-4  0.7317 
 cg04413644   < 1e-4  0.0086 
 cg12049093   < 1e-4  0.1122 
 cg21346589   < 1e-4  0.235 
 cg18527583   < 1e-4  0.0126 
 cg00639635   < 1e-4  0.2032 
 cg22133973   < 1e-4  0.0004 
 cg12644659   < 1e-4  0.7813 
 cg12949927   < 1e-4  0.0915 
 cg20714487   < 1e-4  0.0000 
 cg03701930   < 1e-4  0.5572 
 CARKD   < 1e-4  0.2309 
 NYNRIN   < 1e-4  0.1213 
 IL2RA   < 1e-4  0.8899 
 cg02438164   < 1e-4  0.0029 
 
 
 
 
 
 
 
 
 
 
 
 
Table S7 
  
Methylated Gene 
 P-value  
 Causation  Association 
 cg27424148   < 1e-4  0.8752 
 MIR220B   < 1e-4  0.3568 
 cg16991316   < 1e-4  0.0292 
 cg01433468   < 1e-4  0.4165 
 cg04124260   < 1e-4  0.0587 
 cg06769739   < 1e-4  0.0004 
 cg11989330   < 1e-4  0.0006 
 cg17883371   < 1e-4  0.0075 
 GSTTP1   < 1e-4  0.0016 
 YWHAQ   < 1e-4  0.6393 
 cg25004193   < 1e-4  0.0001 
 cg25757820   < 1e-4  0.2169 
 cg02093808   < 1e-4  0.2378 
 C11orf45   < 1e-4  0.1566 
 cg00850073   < 1e-4  0.0136 
 NME5   < 1e-4  0.1576 
 cg14727987   < 1e-4  0.0011 
 cg10245123   < 1e-4  0.0014 
 MFHAS1   < 1e-4  0.5626 
 cg11388673   < 1e-4  0.6857 
 cg18001780   < 1e-4  0.0127 
 KRT77   < 1e-4  0.0291 
 cg16624888   < 1e-4  0.0000 
 TPT1   < 1e-4  0.2871 
 CCDC70   < 1e-4  0.0186 
 cg01358406   < 1e-4  0.0119 
 cg03608502   < 1e-4  0.1001 
 
 
 
 
 
 
 
Table S8.  A list of 120 DNA methylation sites/genes that were indirectly connected to AD and 
T2DM. 
Methylation 
Site/Gene 
Expressed 
Genes 
P-value Reference Methylation Site 
in the Gene Causation Association  
cg18747197 QKI 0.00004 4.04E-06   
cg19351026 GABRA2 0.00018 1.01E-05   
cg27665808 snoU13 0.00014 1.17E-05   
GSTTP1 RP11-259G18.2 
0.00007 1.55E-05 cg10678937,cg11141652,cg
15242686,cg22666875 
cg12363375 CTD-3025N20.2 0.00021 1.98E-05   
cg16677162 GPX6 0.00011 2.24E-05   
cg13401079 RCOR1 0.00015 2.77E-05   
cg17670237 RP11-259G18.2 0.00015 2.77E-05   
cg07536144 U1 0.00001 4.58E-05   
ABCA10 RP11-86H7.7 
0.0001 4.64E-05 cg13849142,cg14019757,cg
14069205 
cg22463795 GABRA2 0.00019 4.65E-05   
cg01797450 ASS1 8.00E-05 5.03E-05   
cg23454003 PSMB6 9.00E-05 5.45E-05   
cg05455747 ZC3H4 0.00E+00 6.23E-05   
cg17526301 GPX6 3.00E-05 8.06E-05   
cg10061805 PPIAP2 1.80E-04 1.53E-04   
cg02190400 ZC3H4 5.00E-05 1.66E-04   
cg15304404 RXFP4 2.80E-04 1.83E-04   
cg24751928 CTD-2501E16.2 4.00E-05 1.96E-04   
cg17125990 GABRA2 3.00E-05 2.06E-04   
Methylation 
Site/Gene 
Expressed 
Genes 
P-value Reference Methylation Site 
in the Gene Causation Association  
cg00415011 GARNL3 0.00E+00 2.08E-04   
cg23340218 WNT3A 3.00E-05 2.45E-04   
cg26274929 UTP6 5.00E-05 2.66E-04   
cg09977969 CTD-2116F7.1 2.00E-04 2.68E-04   
cg02461269 CTD-3025N20.2 6.00E-05 3.15E-04   
cg02523270 GARNL3 3.60E-04 3.24E-04   
cg09550810 GARNL3 2.00E-05 3.80E-04   
cg07475973 RP11-265D19.6 1.20E-04 3.91E-04   
cg21686890 ABCB6 2.00E-05 3.98E-04   
cg21099148 snoU13 1.90E-04 4.26E-04   
cg01870681 GPX6 1.90E-04 4.40E-04   
cg25112877 WNT3A 1.40E-04 4.63E-04   
cg19711815 RP11-259G18.2 8.00E-05 5.49E-04   
cg06447341 TTC37 3.00E-05 6.86E-04   
ch.2.3048096R ASS1 2.00E-05 7.17E-04   
cg07536144 PLCH1-AS1 9.00E-05 7.44E-04   
cg15426660 snoU13 1.00E-05 7.61E-04   
cg08209099 RP11-259G18.2 7.00E-05 7.85E-04   
cg22891595 GARNL3 1.00E-05 8.71E-04   
cg06181286 CBLN4 0.00E+00 9.85E-04   
cg14739859 RP11-259G18.2 5.00E-05 9.89E-04   
cg12548341 GNAL 1.30E-04 1.06E-03   
Methylation 
Site/Gene 
Expressed 
Genes 
P-value Reference Methylation Site 
in the Gene Causation Association  
cg15426660 SNTB2 9.00E-05 1.16E-03   
cg10059756 GABRA2 4.00E-05 1.21E-03   
cg21205865 snoU13 4.00E-05 1.32E-03   
cg00039801 RP11-259G18.2 6.00E-05 1.35E-03   
cg10316834 snoU13 1.00E-04 1.35E-03   
cg20078879 RPS4X 9.00E-05 1.37E-03   
cg24015081 CTD-2176I21.1 1.80E-04 1.45E-03   
cg25214310 SUGT1 3.70E-04 1.53E-03   
cg14687029 ABCB6 8.00E-05 1.56E-03   
cg05157340 RANBP2 1.40E-04 2.00E-03   
cg06709828 CTD-3025N20.2 0.00E+00 2.08E-03   
cg06112654 SNTB2 4.00E-05 2.09E-03   
cg06112654 snoU13 6.00E-05 2.18E-03   
cg22651787 FAM188B 5.00E-05 2.50E-03   
cg14577406 RBPMS2 0.00E+00 2.58E-03   
cg04854637 SUGT1 3.00E-05 3.27E-03   
cg12180270 GABRA2 2.00E-05 3.31E-03   
cg04606076 RXFP4 1.20E-04 3.32E-03   
cg02486332 CASP12 1.20E-04 3.43E-03   
cg11868247 RP11-351K16.4 7.00E-05 3.50E-03   
cg13001963 RXFP4 0.00E+00 3.99E-03   
cg24430419 snoU13 1.00E-04 4.03E-03   
Methylation 
Site/Gene 
Expressed 
Genes 
P-value Reference Methylation Site 
in the Gene Causation Association  
cg07716131 SAA1 1.60E-04 4.57E-03   
MIR145 RCOR1 
3.00E-05 4.80E-03 cg01310120,cg08537847,cg
11671363,cg22941668,cg2
3917868,cg27083040 
cg16101962 GARNL3 2.00E-05 4.95E-03   
cg10238080 snoU13 6.30E-04 5.01E-03   
cg12094552 SNTB2 5.00E-05 5.25E-03   
cg23346544 ARHGAP20 0.00E+00 5.56E-03   
cg13332807 PKN2 1.30E-04 6.11E-03   
TDGF1 ST6GALNAC6 5.00E-05 7.25E-03 cg06174858 
cg24617444 RUSC1 0.00E+00 7.76E-03   
ANKRD53 CPE 
2.10E-04 7.92E-03 cg00421335,cg01154254,cg
04076766,cg04737087,cg0
5472974,cg05492660,cg06
783668,cg07903989,cg124
28298,cg15165122,cg1800
6568,cg18313051,cg19111
030,cg19244342,cg194900
01,cg20814026,cg2205095
0,cg23060872,cg24573743,
cg27665449 
cg20918393 PPIAP2 9.00E-05 8.20E-03   
cg23925513 RARB 1.20E-04 8.65E-03   
cg18105749 BRSK2 5.00E-05 9.15E-03   
cg16624888 RXFP4 6.00E-05 9.48E-03   
cg09315586 SUGT1 1.00E-05 9.81E-03   
cg20078879 DNAJC1 7.00E-05 1.01E-02   
Methylation 
Site/Gene 
Expressed 
Genes 
P-value Reference Methylation Site 
in the Gene Causation Association  
cg00651087 ZNF114 5.00E-05 1.12E-02   
cg04606076 C2CD2L 1.50E-04 1.22E-02   
cg10061805 FAN1 1.90E-04 1.25E-02   
cg25900943 SNTB2 1.00E-05 1.31E-02   
HRCT1 DCTN2 2.80E-04 1.31E-02 cg02258201,cg05470166 
cg05521150 PMS2CL 5.00E-05 1.44E-02   
cg11868247 CSNK1G1 7.00E-05 1.46E-02   
cg11868247 EIF6 6.00E-05 1.66E-02   
cg24631482 LA16c-444G7.2 0.00005 1.77E-02   
cg04858776 OR2L13 0.00015 1.86E-02   
cg15022039 SRD5A1 0.00033 1.90E-02   
C6orf223 SMO 
0.00003 2.01E-02 cg02213045,cg04386144,cg
09745336,cg10938046,cg1
1201894,cg13900100,cg15
629096,cg16039071,cg189
49415,cg19274606,cg2463
0373,cg25360181 
cg17624891 DGKK 0.00007 2.04E-02   
cg25816127 WNT3A 0 2.08E-02   
cg26686150 FAM213B 0.00001 2.14E-02   
cg19937979 hsa-mir-146a 0.00002 2.15E-02   
cg04819760 FAH 0.00057 2.28E-02   
cg07929768 POTEG 1.60E-04 2.33E-02   
cg26095395 ADRA1B 0.00E+00 2.54E-02   
Methylation 
Site/Gene 
Expressed 
Genes 
P-value Reference Methylation Site 
in the Gene Causation Association  
cg14145524 XRCC5 0.00E+00 2.56E-02   
cg17214023 INPP5F 8.00E-05 2.59E-02   
cg16609139 SDS 1.30E-04 2.74E-02   
ch.11.96774805R RPS4X 3.00E-05 2.79E-02   
ch.10.109266902R RP11-351K16.4 0.00013 2.95E-02   
cg02796279 OR7C1 0.00004 3.29E-02   
cg19937979 NDUFA8 0.00003 3.42E-02   
ch.2.1894803R NUMB 0.00006 3.44E-02   
cg14257429 SNTB2 0.00002 3.66E-02   
cg08122831 RP11-284N8.3 0.00001 3.78E-02   
cg11465213 EXOSC2 0.00006 4.05E-02   
cg05766107 ADCYAP1R1 0.00005 4.08E-02   
cg00895132 ZNF233 0.00003 4.19E-02   
cg19355069 ESD 0.00014 4.32E-02   
cg18978531 C2orf18 0.00009 4.72E-02   
MYCT1 RP11-265D19.6 0.00002 4.76E-02 cg02830467,cg15961007 
cg03257930 FADS6 0.00003 4.81E-02   
cg11540476 RP11-114F3.5 0.00001 4.86E-02   
 
 
 
 
